Trials / Terminated
TerminatedNCT01774604
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 449 (actual)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indomethacin | 100 mg Indomethacin PR x 1 |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-01-24
- Last updated
- 2016-11-04
- Results posted
- 2016-09-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01774604. Inclusion in this directory is not an endorsement.